Biggest News Aggregation in the World
📰 Patients Continued News

Patients Continued News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Patients Continued. Real-time updates on events, politics, business and more.

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease (CTAD) Conference -October 25, 2023 at 05:27 pm EDT

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical...
United States South Korea United Kingdom New Zealand Great Britain Acta Pharmacol

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease (CTAD) Conference - Biogen (NASDAQ:BIIB)

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical Improvement At 18
United States South Korea United Kingdom Great Britain Tsujim Protofibrils Haruo Naito

U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
United States Marni Kottle Biomarin Rareconnections Jeff Ajer Traci Mccarty International Society On Thrombosis

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science